US · ISRG
Intuitive Surgical, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Sunnyvale, CA 94086-5304
- Website
- intuitive.com
Price · as of 2025-12-31
$457.78
Market cap 178.81B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $316.72 | -30.81% |
| Intrinsic Value(DCF) | $295.08 | -35.54% |
| Graham-Dodd Method(GD) | $88.92 | -80.58% |
| Graham Formula(GF) | $222.74 | -51.34% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $58.20 | $71.67 | $191.28 | $14.18 | $44.16 |
| 2012 | $57.18 | $68.28 | $163.16 | $18.77 | $56.98 |
| 2013 | $49.33 | $57.76 | $54.64 | $18.61 | $22.23 |
| 2014 | $54.83 | $68.69 | $8.04 | $15.88 | $3.26 |
| 2015 | $64.49 | $80.32 | $12.25 | $21.15 | $34.24 |
| 2016 | $81.57 | $103.52 | $18.90 | $26.85 | $44.72 |
| 2017 | $146.82 | $133.79 | $51.17 | $23.35 | $45.40 |
| 2018 | $177.92 | $135.75 | $87.93 | $35.41 | $86.98 |
| 2019 | $185.05 | $146.30 | $122.22 | $42.96 | $109.37 |
| 2020 | $244.66 | $163.23 | $37.97 | $41.95 | $17.05 |
| 2021 | $273.69 | $191.85 | $143.90 | $56.53 | $180.86 |
| 2022 | $224.75 | $161.61 | $72.88 | $48.65 | $62.23 |
| 2023 | $391.85 | $254.09 | $142.71 | $62.50 | $112.14 |
| 2024 | $518.26 | $312.65 | $94.29 | $77.98 | $160.74 |
| 2025 | $496.25 | $316.72 | $157.36 | $88.92 | $222.74 |
AI valuation
Our deep-learning model estimates Intuitive Surgical, Inc.'s (ISRG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $316.72
- Current price
- $457.78
- AI upside
- -30.81%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$295.08
-35.54% upside
Graham-Dodd
$88.92
-80.58% upside
Graham Formula
$222.74
-51.34% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ISRG | Intuitive Surgical, Inc. | $457.78 | 178.81B | -31% | -36% | -81% | -51% | 61.57 | 9.94 | 17.60 | 47.34 | 272.61 | 10.15 | 66.00% | 29.27% | 28.38% | 16.79% | 20.67% | 14.58% | 0.02 | — | 4.87 | 3.77 | -0.85 | 2259.00% | 2051.00% | 9103.00% | 1.41% | 1.51 | 20.12% | 0.00% | 0.00% | 1.96% | 58.22 | 68.85 | 17.04 | 41.40 |
| BAX | Baxter International Inc. | $20.37 | 10.48B | +17% | -61% | — | — | -10.55 | 1.65 | 0.90 | 23.68 | -27.93 | -3.19 | 30.05% | -2.74% | -8.51% | -14.62% | -1.88% | -4.18% | 1.63 | -1.06 | 2.31 | 1.31 | 10.49 | 3780.00% | 572.00% | -4222.00% | 3.20% | 0.28 | 1.97% | 3.45% | -36.40% | 39.56% | -58.89 | 56.15 | 1.61 | 2.13 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| BNGO | Bionano Genomics, Inc. | $1.15 | 3.78M | +6,408% | +42% | — | +30,750% | -0.07 | 0.22 | 0.25 | -0.26 | — | 0.30 | 1.23% | -337.87% | -363.98% | -170.33% | -128.38% | -76.97% | 0.77 | -359.80 | 1.06 | 0.38 | -0.19 | -9964.00% | -1479.00% | -4559.00% | -889.15% | -1.85 | -85.22% | 0.00% | 0.00% | 558.30% | -0.25 | -0.37 | 0.83 | -16.59 |
| COO | The Cooper Companies, Inc… | $83.67 | 16.63B | -16% | -60% | -63% | -71% | 44.52 | 2.03 | 4.08 | 18.38 | — | 5.96 | 60.67% | 16.69% | 9.16% | 4.59% | 4.21% | 3.03% | 0.34 | 6.83 | 1.89 | 0.84 | 2.54 | -459.00% | 506.00% | 5054.00% | 2.60% | 0.72 | 4.04% | 0.00% | 0.00% | 1.74% | 28.35 | 44.65 | 4.73 | 3.88 |
| EMBC | Embecta Corp. | $10.26 | 607.6M | +264% | -45% | — | -28% | 6.95 | -1.02 | 0.61 | 6.34 | 33.27 | -0.99 | 62.89% | 30.48% | 8.83% | -13.74% | 39.85% | 8.03% | -2.20 | 3.07 | 2.41 | 1.43 | 4.09 | 2090.00% | -380.00% | 81658.00% | 27.50% | 0.73 | 31.54% | 5.28% | 36.70% | 26.66% | 5.67 | 10.24 | 1.73 | 2.05 |
| HOLX | Hologic, Inc. | $75.36 | 16.82B | +9% | -53% | -75% | -67% | 30.11 | 3.37 | 4.15 | 17.05 | — | 20.82 | 61.00% | 17.42% | 13.80% | 11.12% | 10.86% | 6.23% | 0.52 | 16.73 | 3.75 | 2.87 | 0.65 | -2500.00% | 174.00% | -1964.00% | 5.40% | 1.08 | 16.84% | 0.00% | 0.00% | 4.42% | 24.44 | 18.97 | 4.26 | 4.18 |
| ICUI | ICU Medical, Inc. | $150.58 | 3.72B | -14% | -61% | -83% | -100% | 4947.86 | 1.71 | 1.62 | 14.41 | — | -381.73 | 36.76% | 4.80% | 0.03% | 0.04% | 1.32% | 0.02% | 0.66 | 1.01 | 2.36 | 0.98 | 3.32 | -10061.00% | -638.00% | -2636.00% | 2.53% | 0.36 | 2.82% | 0.00% | 0.00% | 7.11% | 44.00 | 51.26 | 2.11 | 2.21 |
| LUCY | Innovative Eyewear, Inc. | $1.12 | 5.12M | +2,253% | +40,227,901% | — | — | -0.81 | 0.69 | 3.84 | 0.16 | — | 0.73 | 13.15% | -484.20% | -474.60% | -106.00% | -557.55% | -96.74% | 0.00 | — | 12.52 | 10.38 | 0.35 | -5904.00% | 4199.00% | 1643.00% | -111.49% | -9.14 | -493.01% | 0.00% | 0.00% | 0.00% | 0.16 | 0.18 | -0.76 | 0.10 |
| MMSI | Merit Medical Systems, In… | $77.18 | 4.58B | +4% | -60% | -62% | -45% | 35.22 | 2.86 | 2.99 | 14.98 | 715.00 | 8.38 | 48.70% | 12.19% | 8.48% | 8.67% | 7.25% | 5.03% | 0.57 | 6.98 | 4.34 | 2.80 | 1.35 | 493.00% | 1175.00% | 1800.00% | 4.77% | 1.24 | 11.26% | 0.00% | 0.00% | 0.00% | 26.93 | 23.07 | 3.28 | 4.04 |
| NXGL | NEXGEL, Inc. | $1.15 | 12.25M | +3,170% | +17,257% | — | — | -5.85 | 3.34 | 2.21 | -6.97 | — | 5.03 | 31.63% | -40.91% | -37.76% | -62.78% | -61.44% | -31.34% | 0.49 | -43.88 | 2.07 | 1.11 | -0.35 | -1071.00% | 11247.00% | 961.00% | -22.44% | -1.57 | -74.51% | 0.00% | 0.00% | 0.00% | -5.69 | -4.69 | 2.33 | 0.07 |
| RGEN | Repligen Corporation | $128.73 | 7.25B | -26% | -60% | -83% | -84% | 143.73 | 3.34 | 9.52 | 42.30 | — | 11.60 | 47.09% | 8.07% | 6.62% | 2.40% | 2.38% | 1.69% | 0.33 | 2.57 | 8.37 | 6.82 | 0.75 | -28696.00% | 1636.00% | -3410.00% | 1.34% | 0.86 | 4.78% | 0.00% | 0.00% | 0.00% | 116.65 | 74.02 | 9.41 | 5.94 |
| RMD | ResMed Inc. | $256.26 | 37.41B | -10% | -40% | -86% | -35% | 28.88 | 6.78 | 7.86 | 20.96 | 77.17 | 16.47 | 59.36% | 32.75% | 27.22% | 25.86% | 25.33% | 18.62% | 0.14 | 133.66 | 3.44 | 2.16 | -0.19 | 3743.00% | 984.00% | 2918.00% | 4.11% | 1.72 | 29.91% | 0.77% | 22.20% | 3.96% | 23.79 | 24.13 | 7.79 | 13.72 |
| TFX | Teleflex Incorporated | $122.06 | 5.39B | -20% | -55% | — | +315% | -6.06 | 1.76 | 2.75 | 17.49 | — | -7.79 | 56.24% | 2.94% | -45.45% | -24.47% | 1.35% | -12.90% | 0.06 | 0.58 | 2.54 | 0.95 | -0.64 | -146824.00% | -3461.00% | -9972.00% | 0.03% | 0.13 | 0.03% | 1.10% | -6.70% | 36.82% | 90.40 | 3659.08 | 2.66 | 2.01 |
| WST | West Pharmaceutical Servi… | $254.34 | 18.32B | -20% | -57% | -75% | -62% | 36.79 | 5.72 | 5.91 | 24.59 | 2237.77 | 5.94 | 35.89% | 20.09% | 16.06% | 16.85% | 18.68% | 12.48% | 0.13 | 1029.00 | 3.02 | 2.09 | -0.52 | 164.00% | 626.00% | 6965.00% | 2.58% | 1.15 | 17.68% | 0.34% | 12.40% | 2.15% | 28.82 | 37.94 | 5.79 | 12.97 |
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
- CEO
- David J. Rosa
- Employees
- 15.64K
- Beta
- 1.66
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($295.08 ÷ $457.78) − 1 = -35.54% (DCF, example).